{
    "clinical_study": {
        "@rank": "77390", 
        "acronym": "ORBIT-4", 
        "arm_group": [
            {
                "arm_group_label": "Pulmaquin", 
                "arm_group_type": "Experimental", 
                "description": "Pulmaquin: Liquid mixture of liposomally encapsulated and unencapsulated ciprofloxacin"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo: Liquid formulation of empty liposomes"
            }
        ], 
        "brief_summary": {
            "textblock": "This study (ARD-3150-1201, ORBIT-4) will evaluate the safety and efficacy of inhaled\n      Pulmaquin compared to inhaled placebo in subjects who have a confirmed diagnosis of\n      non-cystic fibrosis (non-CF) bronchiectasis with a history of pulmonary exacerbations and\n      chronic P. aeruginosa infections."
        }, 
        "brief_title": "Phase 3 Study With Pulmaquin in Non-CF Bronchiectasis", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Non Cystic Fibrosis Bronchiectasis", 
        "condition_browse": {
            "mesh_term": [
                "Bronchiectasis", 
                "Fibrosis"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a multinational, multicenter, randomized, double-blind, placebo-controlled study to\n      evaluate the safety and efficacy of Pulmaquin compared to placebo in the management of\n      chronic lung infections with P. aeruginosa in subjects with non-CF bronchiectasis with a\n      history of pulmonary exacerbations.\n\n      This study will consist of a Screening Phase, a Double-Blind Phase (6 cycles each consisting\n      of 28-days once daily Pulmaquin or Placebo, and 28 days off treatment) followed by\n      Open-Label Extension (28 days on Pulmaquin)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Confirmed diagnosis of non-CF bronchiectasis\n\n          -  History of P. aeruginosa respiratory infections\n\n          -  At least two pulmonary exacerbations treated with antibiotics in the previous year\n\n        Exclusion Criteria:\n\n          -  Have a clinical diagnosis of CF\n\n          -  Are pregnant"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "255", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02104245", 
            "org_study_id": "ARD-3150-1202"
        }, 
        "intervention": [
            {
                "arm_group_label": "Pulmaquin", 
                "intervention_name": "Pulmaquin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ciprofloxacin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Non Cystic Fibrosis Bronchiectasis, Pulmaquin, Ciprofloxacin, Pseudomonas aeruginosa", 
        "lastchanged_date": "May 30, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kissimmee", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Duluth", 
                        "country": "United States", 
                        "state": "Georgia"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rockhill", 
                        "country": "United States", 
                        "state": "South Carolina"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Spartanburg", 
                        "country": "United States", 
                        "state": "South Carolina"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pulmaquin\u00ae in the Management of Chronic Lung Infections With Pseudomonas Aeruginosa in Patients With Non-Cystic Fibrosis Bronchiectasis, Including 28 Day Open-Label Extension", 
        "overall_contact": {
            "email": "pieretti@aradigm.com", 
            "last_name": "Debbie Pieretti"
        }, 
        "overall_official": {
            "affiliation": "Aradigm Corporation", 
            "last_name": "Juergen Froehlich, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Time to first pulmonary exacerbation (from baseline)", 
            "safety_issue": "Yes", 
            "time_frame": "48 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02104245"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Aradigm Corporation", 
        "sponsors": {
            "collaborator": {
                "agency": "Grifols Therapeutics Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Aradigm Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}